MAGEA3 and cutaneous melanoma: The Glaxo-Smith-Kline (GSK) DERMA trial was a phase 3, double-blind, randomized (2:1) trial that compared, in patients with completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma, a treatment with 13 intramuscular injections of recombinant MAGE-A3 combined with an immunostimulant versus a placebo, over a 27-month period.